Related Experiment Videos
A multicenter study in Malaysia to determine the efficacy and safety of a generic atorvastatin
N Punithavathi1, L M Ong, Y L L Lena
1Clinical Research Centre, Penang Hospital, Residency Road 10990 Pulau Pinang, Malaysia.
Abstract:
A multicenter study was conducted to assess the efficacy of a generic form of Atorvastatin (Ranbaxy's Storvas) in the treatment of Primary Hypercholesterolemia. One hundred and nineteen patients were given 10 mg of Storvas for four weeks and increased to 20 mg if target LDL-Cholesterol was not achieved. LDL-Cholesterol was reduced by 36.6% at four weeks and 37.5% at eight weeks from baseline. Total cholesterol and triglycerides were significantly reduced. There were no drug-related serious adverse events. We conclude that the generic atorvastatin is safe and effective in the treatment of primary hypercholesterolaemia and the results are comparable to published data on innovator atorvastatin.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability Study Design: Single Versus Multiple Dose Studies
Bioequivalence of Drugs: Drugs with Multiple Indications
Bioequivalence studies: Biowaivers